SEER
Seer, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.74
+0.29%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.77
From 52W high−25.54%
Volume22694.00
Market cap$96.07M
P/E (TTM)—
P/S (TTM)6.9x
Div yield—
Key dataNov 4, 2026
Open
$1.77
From 52W high
−25.54%
Volume
22694.00
Market cap
$96.07M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
32.2
MomentumView details →
1D Return
+0.29%
YTD Return
−5.46%
SummaryUpdated Jun 1, 2026
Seer, Inc. (NASDAQ:SEER) is a life sciences company founded in 2017 and headquartered in Redwood City, California. The company went public in December 2020 and specializes in developing and commercializing advanced proteomics technology to help researchers decode the complexities of the human proteome. Seer has positioned itself as a pioneer in deep, unbiased proteomics analysis at scale, serving over 135 customers across 20 countries through its flagship Proteograph Product Suite.
Similar companies
Latest newsMore news →
Seer announced that its Special Committee concluded its review and rejected recent acquisition proposals, leaving Seer to remain an independent public company.6d agoSeer announced that it will report its third-quarter 2026 financial results on November 10, 2026, with a webcast conference call scheduled for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).14d ago